MDR1-associated resistance to artesunate+mefloquine does not impair blood-stage parasite fitness in a rodent malaria model

Infection, Genetics and Evolution

Volumn 14, Issue 1, 2013, Pages 340-346

  Rodrigues, Louise ^a   Henriques, Gisela ^a   Cravo, Pedro ^a,b  

^a INSTITUTO DE HIGIENE E MEDICINA TROPICAL   (Portugal)

^b FEDERAL UNIVERSITY OF GOIÁS   (Brazil)

Author keywords

Artemisinin combination treatment; Drug resistance; Fitness; Malaria; Plasmodium chabaudi

Indexed keywords

ARTESUNATE PLUS MEFLOQUINE; MULTIDRUG RESISTANCE PROTEIN 1;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBIOTIC THERAPY; ANTIMALARIAL DRUG RESISTANCE; ARTICLE; BLOOD PARASITE; CONTROLLED STUDY; DNA EXTRACTION; DOSE RESPONSE; DRUG DOSE INCREASE; GENE; GENE DUPLICATION; GENE FUNCTION; GENE SEQUENCE; IN VIVO STUDY; INOCULATION; MALARIA; MALE; MDR1 GENE; MICROBIAL GROWTH; MICROBIOLOGICAL PARAMETERS; MOLECULAR CLONING; MOLECULAR DYNAMICS; MOUSE; NONHUMAN; PARASITE FITNESS; PARASITEMIA; PLASMODIUM CHABAUDI; POPULATION ABUNDANCE; PRIORITY JOURNAL;

ANIMALS; ANTIMALARIALS; ARTEMISININS; DISEASE MODELS, ANIMAL; DRUG RESISTANCE; HOST-PATHOGEN INTERACTIONS; MALE; MICE; MULTIDRUG RESISTANCE-ASSOCIATED PROTEINS; PARASITEMIA; PLASMODIUM CHABAUDI; PROTOZOAN PROTEINS;

EID: 84873297127     PISSN: 15671348     EISSN: 15677257     Source Type: Journal    
DOI: 10.1016/j.meegid.2012.12.011     Document Type: Article

References (46)

1. 2+ ATPase), tctp, mdr1, and cg10. Antimicrob. Agents Chemother. 2006, 50:480-489.
2. Alker A.P., Lim P., Sem R., et al. Pfmdr1 and in vivo resistance to artesunate-mefloquine in falciparum malaria on the Cambodian-Thai border. Am. J. Trop. Med. Hyg. 2007, 76:641-647.
3. Anderson J.B. Evolution of antifungal-drug resistance. Mechanisms and pathogen fitness. Nat. Rev. Microbiol. 2005, 3:547-556.
4. Andersson D.I., Hughes D. Antibiotic resistance and its cost: is it possible to reverse resistance?. Nat. Rev. Microbiol. 2010, 8:260-271.
5. Babiker H.A. Seasonal fluctuation of drug-resistant malaria parasites: a sign of fitness cost. Trends Parasitol. 2009, 25:351-352.
6. Babiker H.A., Hastings I.M., Swedberg G. Impaired fitness of drug-resistant malaria parasites: evidence and implication on drug-deployment policies. Expert Rev. Anti. Infect. Ther. 2009, 7:581-593.
7. Borges S., Cravo P., Creasey A., et al. Genomewide scan reveals amplification of mdr1 as a common denominator of resistance to mefloquine, lumefantrine, and artemisinin in Plasmodium chabaudi malaria parasites. Antimicrob. Agents Chemother. 2011, 55:4858-4865.
8. Bottger E.C., Springer B. Tuberculosis: drug resistance, fitness, and strategies for global control. Eur. J. Pediatr. 2008, 167:141-148.
9. Brown K.M., Costanzo M.S., Xu W., et al. Compensatory mutations restore fitness during the evolution of dihydrofolate reductase. Mol. Biol. Evol. 2010, 27:2682-2690.
10. Carlton J.M., Hayton K., Cravo P.V., et al. Of mice and malaria mutants: unravelling the genetics of drug resistance using rodent malaria models. Trends Parasitol. 2001, 17:236-242.
11. Carrara V.I., Zwang J., Ashley E.A., et al. Changes in the treatment responses to artesunate-mefloquine on the northwestern border of Thailand during 13years of continuous deployment. PLoS One 2009, 4:e4551.
12. Chaijaroenkul W., Wisedpanichkij R., Na-Bangchang K. Monitoring of in vitro susceptibilities and molecular markers of resistance of Plasmodium falciparum isolates from Thai-Myanmar border to chloroquine, quinine, mefloquine and artesunate. Acta Trop. 2010, 113:190-194.
13. Chavchich M., Gerena L., Peters J., et al. Role of pfmdr1 amplification and expression in induction of resistance to artemisinin derivatives in Plasmodium falciparum. Antimicrob. Agents Chemother. 2010, 54:2455-2464.
14. Cheesman S., Creasey A., Degnan K., et al. Validation of pyrosequencing for accurate and high throughput estimation of allele frequencies in malaria parasites. Mol. Biochem. Parasitol. 2007, 152:213-219.
15. Chen N., Chavchich M., Peters J.M., et al. Deamplification of pfmdr1-containing amplicon on chromosome 5 in Plasmodium falciparum is associated with reduced resistance to artelinic acid in vitro. Antimicrob. Agents Chemother. 2010, 54:3395-3401.
16. Costanzo M.S., Hartl D.L. The evolutionary landscape of antifolate resistance in Plasmodium falciparum. J. Genet. 2011, 90:187-190.
17. Ding X.C., Beck H.P., Raso G. Plasmodium sensitivity to artemisinins: magic bullets hit elusive targets. Trends Parasitol. 2011, 27:73-81.
18. Dondorp A.M., Nosten F., Yi P., et al. Artemisinin resistance in Plasmodium falciparum malaria. N. Engl. J. Med. 2009, 361:455-467.
19. Felger I., Beck H.P. Fitness costs of resistance to antimalarial drugs. Trends Parasitol. 2008, 24:331-333.
20. Gagneux S. Fitness cost of drug resistance in Mycobacterium tuberculosis. Clin. Microbiol. Infect. 2009, 15(Suppl. 1):66-68.
21. Hunt P., Fawcett R., Carter R., et al. Estimating SNP proportions in populations of malaria parasites by sequencing: validation and applications. Mol. Biochem. Parasitol. 2005, 143:173-182.
22. Kublin J.G., Cortese J.F., Njunju E.M., et al. Reemergence of chloroquine-sensitive Plasmodium falciparum malaria after cessation of chloroquine use in Malawi. J. Infect. Dis. 2003, 187:1870-1875.
23. Laufer M.K., Thesing P.C., Eddington N.D., et al. Return of chloroquine antimalarial efficacy in Malawi. N. Engl. J. Med. 2006, 355:1959-1966.
24. Lim P., Alker A.P., Khim N., et al. Pfmdr1 copy number and arteminisin derivatives combination therapy failure in falciparum malaria in Cambodia. Malar. J. 2009, 8:11.
25. Lim P., Wongsrichanalai C., Chim P., et al. Decreased in vitro susceptibility of Plasmodium falciparum isolates to artesunate, mefloquine, chloroquine, and quinine in Cambodia from 2001 to 2007. Antimicrob. Agents Chemother. 2010, 54:2135-2142.
26. Mackinnon M.J., Read A.F. Selection for high and low virulence in the malaria parasite Plasmodium chabaudi. Proc. Biol. Sci. 1999, 266:741-748.
27. Maisnier-Patin S., Andersson D.I. Adaptation to the deleterious effects of antimicrobial drug resistance mutations by compensatory evolution. Res. Microbiol. 2004, 155:360-369.
28. Mita T., Kaneko A., Lum J.K., et al. Expansion of wild type allele rather than back mutation in pfcrt explains the recent recovery of chloroquine sensitivity of Plasmodium falciparum in Malawi. Mol. Biochem. Parasitol. 2004, 135:159-163.
29. Nilsson A.I., Zorzet A., Kanth A., et al. Reducing the fitness cost of antibiotic resistance by amplification of initiator tRNA genes. Proc. Natl. Acad. Sci. USA 2006, 103:6976-6981.
30. Ord R., Alexander N., Dunyo S., et al. Seasonal carriage of pfcrt and pfmdr1 alleles in Gambian Plasmodium falciparum imply reduced fitness of chloroquine-resistant parasites. J. Infect. Dis. 2007, 196:1613-1619.
31. Osman M.E., Mockenhaupt F.P., Bienzle U., et al. Field-based evidence for linkage of mutations associated with chloroquine (pfcrt/pfmdr1) and sulfadoxine-pyrimethamine (pfdhfr/pfdhps) resistance and for the fitness cost of multiple mutations in P. falciparum. Infect. Genet. Evol. 2007, 7:52-59.
32. Phyo A.P., Nkhoma S., Stepniewska K., et al. Emergence of artemisinin-resistant malaria on the western border of Thailand: a longitudinal study. Lancet 2012, 379:1960-1966.
33. Pickard A.L., Wongsrichanalai C., Purfield A., et al. Resistance to antimalarials in Southeast Asia and genetic polymorphisms in pfmdr1. Antimicrob. Agents Chemother. 2003, 47:2418-2423.
34. Plowe C.V., Djimde A., Bouare M., et al. Pyrimethamine and proguanil resistance-conferring mutations in Plasmodium falciparum dihydrofolate reductase: polymerase chain reaction methods for surveillance in Africa. Am. J. Trop. Med. Hyg. 1995, 52:565-568.
35. Preechapornkul P., Imwong M., Chotivanich K., et al. Plasmodium falciparum pfmdr1 amplification, mefloquine resistance, and parasite fitness. Antimicrob. Agents Chemother. 2009, 53:1509-1515.
36. Price R., Robinson G., Brockman A., et al. Assessment of pfmdr 1 gene copy number by tandem competitive polymerase chain reaction. Mol. Biochem. Parasitol. 1997, 85:161-169.
37. Price R.N., Cassar C., Brockman A., et al. The pfmdr1 gene is associated with a multidrug-resistant phenotype in Plasmodium falciparum from the western border of Thailand. Antimicrob. Agents Chemother. 1999, 43:2943-2949.
38. Price R.N., Uhlemann A.C., Brockman A., et al. Mefloquine resistance in Plasmodium falciparum and increased pfmdr1 gene copy number. Lancet 2004, 364:438-447.
39. Rodrigues L.A., Henriques G., Borges S.T., et al. Experimental evolution of resistance to artemisinin combination therapy results in amplification of the mdr1 gene in a rodent malaria parasite. PLoS One 2010, 5:e11593.
40. Rogers W.O., Sem R., Tero T., et al. Failure of artesunate-mefloquine combination therapy for uncomplicated Plasmodium falciparum malaria in southern Cambodia. Malar. J. 2009, 8:10.
41. Sá J.M., Chong J.L., Wellems T.E. Malaria drug resistance. New observations and developments. Essays Biochem. 2011, 51:137-160.
42. Temu M.J., Kaale E., Marawiti M. Storage of antimalarials at household level and associated factors in Kiromo ward, Bagamoyo Tanzania. Afr. Health Sci. 2006, 6:43-48.
43. Valderramos S.G., Fidock D.A. Transporters involved in resistance to antimalarial drugs. Trends Pharmacol. Sci. 2006, 11:594-601.
44. Walliker D., Hunt P., Babiker H. Fitness of drug-resistant malaria parasites. Acta Trop. 2005, 94:251-259.
45. Wongsrichanalai C., Meshnick S.R. Declining artesunate-mefloquine efficacy against falciparum malaria on the Cambodia-Thailand border. Emerg. Infect. Dis. 2008, 14:716-719.
46. World Health Organization 2011. World Malaria Report 2011. WHO: Geneva. http://www.who.int/malaria/world_malaria_report_2011/9789241564403_eng.pdf.